A Systematic Review of Models Used in Cost-Effectiveness of Treatments in Spondyloarthritis

This review was aimed to evaluate health economic models used in evaluations of different treatment strategies spondyloarthritis (SpA). Model-based evaluation studies are increasing and complex with short-term long-term horizon applied investigate the cost-effectiveness SpA treatments. The objective this study carry out a systematic evolution SpA. Electronic searches within MEDLINE EMBASE were carried using predefined search strategy. Inclusion exclusion criteria select relevant studies. Data on country, intervention, perspective, type model, time horizon, types costs effectiveness measurement extracted. Eighteen described 22 publications, which 81.8% European. Study perspectives included societal (n=6), healthcare system payer (n=14), or patient government (n=1). Time ranged from 52 weeks lifetime. Markov model most frequently only one individual simulation accounting for uncertainty multiple parameters reported. Most compared biologics (including TNFi/biosimilar IL-17A antibody) conventional care (NSAIDs) because high prize. Only half took indirect into account. Modeling is importance treatment. Long-term especially should be considered when comparing alternatives order provide more information policy makers clinicians.